Casey LippmeierEvery podcast appearance, updated as new ones drop

Powered by Protein Production Technology International Scaling novel lipids from promising science to commercial production brings a unique set of challenges. In infant nutrition, where safety, purity, consistency, and clinical evidence are essential, the journey from innovation to a market-ready ingredient demands more than breakthrough biology. In this episode of the Protein Production Technology International Podcast, Nick Bradley is joined by Alex, Ernesto, and Casey from Checkerspot and the wider biotechnology industry to explore the realities of commercializing novel lipids for infant nutrition and beyond. Using the story of fermentation-derived DHA as a starting point, the panel reflects on what it takes to bring a novel ingredient into widespread use. The discussion covers the challenges that can be less visible in success stories: scale-up difficulties, expensive early production batches, regulatory work, finding customers, achieving viable production economics, and building the capacity to supply them consistently. The speakers examine how advances in precision fermentation, synthetic biology, and AI-enabled design-build-test cycles are changing what is possible. They also discuss the enduring challenges of industrial biotechnology, including the gap between laboratory performance and manufacturing robustness, and why strains and processes must be designed with commercial production in mind. For infant nutrition, the conversation highlights the importance of demonstrating that fermentation-derived ingredients are structurally equivalent, safe, and consistently produced to the required standards of purity and quality. Data and clinical evidence remain central to customer confidence and adoption. The panel also looks ahead to the potential for designing lipids around specific nutritional and functional needs, including innovations such as high-sn-2-palmitate OPO. Beyond infant formula, novel lipids may have applications across food, nutrition, personal care, and other markets. A central theme throughout the discussion is the need to balance technological possibility with market demand. Successful commercialization starts with a real customer need, a clear understanding of ingredient economics, and a technical approach capable of meeting both. The Future of Protein Production is connecting companies working to make the global protein system more sustainable, kind and fair for the planet, people, and animals. To find out more about our platform click here: https://www.futureofproteinproduction.com/ To read the most recent edition of Protein Production Technology, our multi-media magazine, click here: https://www.futureofproteinproduction.com/ #FutureOfProteinProduction #ProteinProductionTechnolog

Powered by Protein Production Technology International A breakthrough ingredient or production process may create headlines, but can it create a defensible business? In this episode of the Protein Production Technology International podcast, Nick Bradley was joined by Kerry Rees and Andrew Tindall of HGF, alongside Gilbert Verschelling of The Protein Brewery, Tim Fronzek of Nosh.bio, and Casey Lippmeier of Checkerspot, to explore how alternative protein companies can build intellectual property strategies that support long-term commercial success. The panel discussed why effective IP management extends far beyond filing patents, examining how founders can align protection strategies with business objectives, fundraising plans, partnerships, and commercialization roadmaps. The conversation explored the balance between patents and trade secrets, the risks of over-filing, and how companies can ensure their most valuable innovations remain protected as they scale. The speakers also shared insights into what investors look for when assessing technology businesses, explaining why strong IP portfolios can strengthen a company's position but are rarely enough on their own. Market traction, execution capability, regulatory progress, and commercial readiness all play critical roles in building investor confidence. From collaboration agreements and freedom-to-operate considerations to licensing strategies and enforcement, the discussion offered practical guidance for founders navigating one of the most important - and often misunderstood - aspects of building an alternative protein company. A must-listen for founders, R&D leaders, investors, legal teams, and anyone seeking to transform innovation into a scalable and defensible business.